Revolutionary Injectable Technology
RepliCel is a regenerative medicine company developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function.
DermaPrecise™
Next-Gen Dermal Injection Technology
DermaPrecise™ is a next-generation dermal injector designed to provide an improved level of control and precision for intradermal (dermis)
and subcutaneous (extracellular matrix & fat) injections.
More About DermaPrecise™  
Press Release
Reschedule Meeting, Supplemental Disclosure for Transaction involving the Sale of Assets and Board Update
1 days ago Dec 20, 2024 RepliCel Life Sciences Reschedules Meeting, Provides Supplemental Disclosure for Transaction involving the Sale of Assets...
Shareholders that have questions are encouraged to contact Andrew Schutte at info@replicel.com or call (604) 248-8730
16 days ago Dec 05, 2024 Shareholders that have questions are encouraged to contact Andrew Schutte at: info@replicel.com or call (604)...
Information Circular and Form of Proxy for AGM and Special Meeting 2024 for Download
17 days ago Dec 04, 2024 RepliCel Life Sciences Inc. AGM and Special Shareholder Meeting PDFs Available for Download:RepliCel - Information...